What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in mortality or CLD at 28/30 days (low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.05 [0.73, 1.52]
  2 studies · 64 participants
  Low

Intervention not reported

It is very uncertain whether the intervention changes mortality to 28 days (very low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.31 [0.52, 3.29]
  2 studies · 64 participants
  Very low

Intervention not reported

The intervention showed no clear difference in CLD at 28 days (low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 0.93 [0.53, 1.64]
  2 studies · 64 participants
  Low

Intervention not reported

The intervention showed no clear difference in CLD at 36 weeks' PMA (low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.25 [0.43, 3.63]
  1 study · 26 participants
  Low

Intervention not reported

The intervention showed no clear difference in CLD among survivors to 28 days (low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.58, 1.63]
  2 studies · 50 participants
  Low

Intervention not reported

The intervention showed no clear difference in CLD among survivors to 36 weeks' PMA (low certainty).

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  RR 1.04 [0.38, 2.87]
  1 study · 22 participants
  Low

Intervention not reported

• Cromolyn sodium for the prevention of chronic lung disease in preterm infants 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Low